Destiny Pharma plc (LON:DEST – Get Free Report) shares dropped 30.1% on Wednesday . The stock traded as low as GBX 2.55 ($0.03) and last traded at GBX 3 ($0.04). Approximately 4,179,453 shares were traded during trading, an increase of 484% from the average daily volume of 715,908 shares. The stock had previously closed at GBX 4.29 ($0.05).
Destiny Pharma Price Performance
The stock has a market capitalization of £2.87 million, a price-to-earnings ratio of -50.00 and a beta of 0.22. The stock’s 50 day simple moving average is GBX 3 and its 200-day simple moving average is GBX 7.31.
About Destiny Pharma
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.
Recommended Stories
- Five stocks we like better than Destiny Pharma
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How to Calculate Inflation Rate
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- 3 Stocks to Consider Buying in October
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
